Optimization of GPR40 Agonists for Type 2 Diabetes

[Image: see text] GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patients in phase II clinical tria...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liu, Jiwen (Jim), Wang, Yingcai, Ma, Zhihua, Schmitt, Mike, Zhu, Liusheng, Brown, Sean P., Dransfield, Paul J., Sun, Ying, Sharma, Rajiv, Guo, Qi, Zhuang, Run, Zhang, Jane, Luo, Jian, Tonn, George R., Wong, Simon, Swaminath, Gayathri, Medina, Julio C., Lin, Daniel C.-H., Houze, Jonathan B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2014
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
https://ncbi.nlm.nih.gov/pubmed/24900872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400501x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados